Pharmacological Activation of Mitochondrial Biogenesis for the Treatment of Various Pathologies

Whitney S. Gibbs, Natalie E. Scholpa, Craig C. Beeson, Rick G. Schnellmann

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Mitochondrial dysfunction is a key pathophysiological mediator in a variety of disease states, including cardiovascular disease, metabolic syndrome, neurodegeneration, and acute organ injury. Pharmacological activation of mitochondrial biogenesis enhances mitochondrial content and oxidative metabolism and improves organ function in conditions involving mitochondrial dysfunction. Due to the complexity of signaling cascades and transcriptional complexes that promote the assembly and function of mitochondria, identification of specific activators of mitochondrial biogenesis is limited. This chapter provides rationale for mitochondrial biogenesis as a therapeutic strategy, discusses the role of mitochondrial dysfunction in acute and chronic disease, and outlines the current state of pharmacological activators of mitochondrial biogenesis and their effects on disease outcomes.

Original languageEnglish (US)
Title of host publicationMitochondrial Dysfunction Caused by Drugs and Environmental Toxicants
PublisherWiley
Pages569-592
Number of pages24
Volume2-2
ISBN (Electronic)9781119329725
ISBN (Print)9781119329701
DOIs
StatePublished - Feb 21 2018

Keywords

  • Disease outcomes
  • Mitochondrial homeostasis
  • Oxidative metabolism
  • Therapeutics

ASJC Scopus subject areas

  • General Chemistry
  • General Pharmacology, Toxicology and Pharmaceutics
  • General Biochemistry, Genetics and Molecular Biology

Fingerprint

Dive into the research topics of 'Pharmacological Activation of Mitochondrial Biogenesis for the Treatment of Various Pathologies'. Together they form a unique fingerprint.

Cite this